Skip Navigation



Carcinogenesis Advance Access published online on March 28, 2003
Carcinogenesis, doi:10.1093/carcin/bgg051
© 2003 by Oxford University Press
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
24/6/1111    most recent
bgg051v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Chen, Z.
Right arrow Articles by Wang, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Z.
Right arrow Articles by Wang, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

CARCINOGENESIS

Defining the function of XPC protein in psoralen and cisplatin-mediated DNA repair and mutagenesis

Zhiwen Chen 1, Xiaoxin Susan Xu 1, Jin Yang 1, Gan Wang 1*

1 Institute of Environmental Health Sciences, Wayne State University, 2727 Second Avenue, Detroit, MI 48201

* Corresponding author. E-mail: g.wang{at}wayne.edu.

Received 30 May 2002 ; revised 18 December 2002 ; accepted 14 March 2003

Abstract

DNA damage recognition plays an important role in DNA repair and mutagenesis. Failure to recognize DNA damage may lead to DNA replication without damage repair as well as mutation accumulation. Mutations can lead to many disease conditions. XPC is a DNA damage recognition protein that binds to damaged DNA templates at very early stage during the DNA repair process. We have studied the role of the XPC protein in DNA cross-link reagents, psoralen and cisplatin, mediated DNA repair and mutagenesis. When psoralen and cisplatin-damaged plasmid DNA was transfected into xeroderma pigmentosum group C (XPC) cells, which were defective in the XPC gene, very distinct mutation frequency and spectrum was observed: a decreased mutation frequency for psoralen-damaged plasmid and an increased mutation frequency for cisplatin-damaged plasmid; in contrast, most mutations generated by psoralen in XPC cells were T-to-G transversions and most mutations generated by cisplatin in XPC cells were large deletions. We also determined the DNA repair ability of XPC cells by both host cell reactivation (HCR) assay and in vitro DNA repair assay. The HCR results showed greatly reduced host cell reactivation of a luciferase reporter for both psoralen and cisplatin-damaged plasmid DNA in XPC cells. The in vitro DNA repair results revealed a defective repair capacity for both psoralen and cisplatin-damaged plasmid DNA in nuclear extract prepared from XPC cells. However, this defective DNA repair activity was partially restored when a functional XPC protein was supplemented into the XPC nuclear extract prior to the reaction. These results suggest that the XPC protein DNA damage recognition function plays a crucial role in DNA repair initiation and mutation avoidance and XPC defects may lead to increased mutations and high risk for disease progression.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
J. Zhao, A. Jain, R. R. Iyer, P. L. Modrich, and K. M. Vasquez
Mismatch repair and nucleotide excision repair proteins cooperate in the recognition of DNA interstrand crosslinks
Nucleic Acids Res., July 1, 2009; 37(13): 4420 - 4429.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Chen, J. Yang, G. Wang, B. Song, J. Li, and Z. Xu
Attenuated Expression of Xeroderma Pigmentosum Group C Is Associated with Critical Events in Human Bladder Cancer Carcinogenesis and Progression
Cancer Res., May 15, 2007; 67(10): 4578 - 4585.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. L. Fischer, E. M. Mihelc, K. E. Pollok, and M. L. Smith
Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair
Mol. Cancer Ther., January 1, 2007; 6(1): 355 - 361.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. L. Colton, X. S. Xu, Y. A. Wang, and G. Wang
The Involvement of Ataxia-telangiectasia Mutated Protein Activation in Nucleotide Excision Repair-facilitated Cell Survival with Cisplatin Treatment
J. Biol. Chem., September 15, 2006; 281(37): 27117 - 27125.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
B. Liedert, D. Pluim, J. Schellens, and J. Thomale
Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei.
Nucleic Acids Res., January 1, 2006; 34(6): e47 - e47.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Yang, Z. Chen, Y. Liu, R. J. Hickey, and L. H. Malkas
Altered DNA Polymerase {iota} Expression in Breast Cancer Cells Leads to a Reduction in DNA Replication Fidelity and a Higher Rate of Mutagenesis
Cancer Res., August 15, 2004; 64(16): 5597 - 5607.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
G. Wang, L. Chuang, X. Zhang, S. Colton, A. Dombkowski, J. Reiners, A. Diakiw, and X. S. Xu
The initiative role of XPC protein in cisplatin DNA damaging treatment-mediated cell cycle regulation
Nucleic Acids Res., April 23, 2004; 32(7): 2231 - 2240.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.